244
Participants
Start Date
June 1, 2019
Primary Completion Date
September 15, 2020
Study Completion Date
September 28, 2020
Empagliflozin
Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
Usual care group
Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
Balochistan Medical Center, Quetta
Lady Reading Hospital, Peshawar
Post Graduate Medical Institute, Peshawar
Hanif Medical Center, Islamabad
Shifa International Hospital, Islamabad
Diabetes Institute of Pakistan, Lahore
Jinnah Hospital, Lahore
National Defence Center, Lahore
Al-Khaliq Hospital, Multan Khurd
Fatimiyah Hospital, Karachi
National Institute of Cardiovascular Disease, Karachi
Lead Sponsor
Getz Pharma
INDUSTRY